CY1107687T1 - Χρηση της sarp-1 για τη θεραπευτικη αντιμετωπιση και/ή προληψη της σκληροδερμιας - Google Patents
Χρηση της sarp-1 για τη θεραπευτικη αντιμετωπιση και/ή προληψη της σκληροδερμιαςInfo
- Publication number
- CY1107687T1 CY1107687T1 CY20071100851T CY071100851T CY1107687T1 CY 1107687 T1 CY1107687 T1 CY 1107687T1 CY 20071100851 T CY20071100851 T CY 20071100851T CY 071100851 T CY071100851 T CY 071100851T CY 1107687 T1 CY1107687 T1 CY 1107687T1
- Authority
- CY
- Cyprus
- Prior art keywords
- sarp
- scleroderma
- prevention
- therapeutic treatment
- treatment
- Prior art date
Links
- 102100030054 Secreted frizzled-related protein 2 Human genes 0.000 title abstract 3
- 108050007987 Secreted frizzled-related protein 2 Proteins 0.000 title abstract 3
- 206010039710 Scleroderma Diseases 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- 201000009594 Systemic Scleroderma Diseases 0.000 abstract 1
- 206010042953 Systemic sclerosis Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Abstract
Η παρούσα εφεύρεση αφορά στη χρήση της SARP-1 (εκκρινόμενη σχετική με την απόπτωση πρωτεΐνη 1) για την παρασκευή ενός φαρμάκου για τη θεραπευτική αντιμετώπιση και/ή πρόληψη της σκληροδερμίας, ιδίως της συστηματικής σκλήρυνσης.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00126771 | 2000-12-06 | ||
EP01118888 | 2001-08-17 | ||
EP01995681A EP1411970B1 (en) | 2000-12-06 | 2001-11-30 | Use of sarp-1 for the treatment and/or prevention of scleroderma |
PCT/EP2001/013992 WO2002046225A2 (en) | 2000-12-06 | 2001-11-30 | Use of sarp-1 for the treatment and/or prevention of scleroderma |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1107687T1 true CY1107687T1 (el) | 2012-05-23 |
Family
ID=26071647
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20071100851T CY1107687T1 (el) | 2000-12-06 | 2007-06-28 | Χρηση της sarp-1 για τη θεραπευτικη αντιμετωπιση και/ή προληψη της σκληροδερμιας |
Country Status (30)
Country | Link |
---|---|
US (2) | US7341995B2 (el) |
EP (2) | EP1411970B1 (el) |
JP (1) | JP2004525869A (el) |
KR (1) | KR100804885B1 (el) |
CN (1) | CN1323716C (el) |
AT (1) | ATE359808T1 (el) |
AU (2) | AU2636602A (el) |
BG (1) | BG107941A (el) |
BR (1) | BR0115983A (el) |
CA (1) | CA2428092A1 (el) |
CY (1) | CY1107687T1 (el) |
CZ (1) | CZ20031855A3 (el) |
DE (1) | DE60128009T2 (el) |
DK (1) | DK1411970T3 (el) |
EA (1) | EA005973B1 (el) |
EE (1) | EE200300213A (el) |
ES (1) | ES2281463T3 (el) |
HK (1) | HK1068106A1 (el) |
HR (1) | HRP20030426A2 (el) |
HU (1) | HUP0302738A3 (el) |
IL (1) | IL156069A0 (el) |
MX (1) | MXPA03005027A (el) |
NO (1) | NO20032597D0 (el) |
NZ (1) | NZ525774A (el) |
PL (1) | PL365316A1 (el) |
PT (1) | PT1411970E (el) |
SK (1) | SK8472003A3 (el) |
UA (1) | UA83790C2 (el) |
WO (1) | WO2002046225A2 (el) |
YU (1) | YU45103A (el) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20000070879A (ko) * | 1997-02-06 | 2000-11-25 | 브루스 엠. 에이센, 토마스 제이 데스로저 | 인간 에스디에프-5 단백질 및 조성물 |
US7585840B2 (en) | 2002-04-10 | 2009-09-08 | Merck Serono S.A. | Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease |
WO2003084560A2 (en) | 2002-04-10 | 2003-10-16 | Applied Research Systems Ars Holding N.V. | Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis |
US9046537B2 (en) * | 2003-09-22 | 2015-06-02 | Enzo Biochem, Inc. | Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain |
SE0400489D0 (sv) * | 2004-02-27 | 2004-02-27 | Biovitrum Ab | Therapeutic proteins |
ES2905923T3 (es) | 2005-02-08 | 2022-04-12 | Genzyme Corp | Anticuerpos de TGFbeta |
WO2007055397A1 (en) * | 2005-11-08 | 2007-05-18 | Foundation For Biomedical Research And Innovation | Method of treatment for ischemic heart disease |
WO2009074637A1 (en) * | 2007-12-13 | 2009-06-18 | Merck Serono S.A. | Sarp-1 fusion proteins and uses thereof |
HUE027481T2 (en) * | 2011-03-11 | 2016-09-28 | Celgene Corp | Methods of treating cancer with 3- (5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl) -piperidine-2,6-dione |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2855189A (en) * | 1988-01-25 | 1989-07-27 | Baker Cummins Dermatologicals, Inc. | Method of treating fibrotic disorders |
US5266575A (en) * | 1991-11-06 | 1993-11-30 | Minnesota Mining And Manufacturing Company | 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines |
US5747639A (en) * | 1996-03-06 | 1998-05-05 | Amgen Boulder Inc. | Use of hydrophobic interaction chromatography to purify polyethylene glycols |
TW555765B (en) * | 1996-07-09 | 2003-10-01 | Amgen Inc | Low molecular weight soluble tumor necrosis factor type-I and type-II proteins |
DE69735375T3 (de) * | 1996-09-24 | 2010-09-02 | Tanox, Inc., Houston | Genfamilie von apoptose-verwandten peptiden, dadurch kodierte peptide und verfahren zu deren herstellung |
US5858715A (en) * | 1997-01-29 | 1999-01-12 | Incyte Pharmaceuticals, Inc. | Human apoptosis-associated protein |
KR20000070879A (ko) * | 1997-02-06 | 2000-11-25 | 브루스 엠. 에이센, 토마스 제이 데스로저 | 인간 에스디에프-5 단백질 및 조성물 |
CN100480266C (zh) * | 1998-10-16 | 2009-04-22 | 拜奥根Idec马萨诸塞公司 | 干扰素-β融合蛋白及用途 |
-
2001
- 2001-11-30 SK SK847-2003A patent/SK8472003A3/sk not_active Application Discontinuation
- 2001-11-30 PL PL01365316A patent/PL365316A1/xx not_active Application Discontinuation
- 2001-11-30 HU HU0302738A patent/HUP0302738A3/hu unknown
- 2001-11-30 EP EP01995681A patent/EP1411970B1/en not_active Expired - Lifetime
- 2001-11-30 YU YU45103A patent/YU45103A/sh unknown
- 2001-11-30 DE DE60128009T patent/DE60128009T2/de not_active Expired - Lifetime
- 2001-11-30 WO PCT/EP2001/013992 patent/WO2002046225A2/en active Search and Examination
- 2001-11-30 AT AT01995681T patent/ATE359808T1/de active
- 2001-11-30 AU AU2636602A patent/AU2636602A/xx active Pending
- 2001-11-30 KR KR1020037007278A patent/KR100804885B1/ko not_active IP Right Cessation
- 2001-11-30 CN CNB018223389A patent/CN1323716C/zh not_active Expired - Fee Related
- 2001-11-30 US US10/432,256 patent/US7341995B2/en not_active Expired - Fee Related
- 2001-11-30 ES ES01995681T patent/ES2281463T3/es not_active Expired - Lifetime
- 2001-11-30 BR BR0115983-6A patent/BR0115983A/pt not_active IP Right Cessation
- 2001-11-30 PT PT01995681T patent/PT1411970E/pt unknown
- 2001-11-30 EE EEP200300213A patent/EE200300213A/xx unknown
- 2001-11-30 EA EA200300639A patent/EA005973B1/ru not_active IP Right Cessation
- 2001-11-30 NZ NZ525774A patent/NZ525774A/xx unknown
- 2001-11-30 DK DK01995681T patent/DK1411970T3/da active
- 2001-11-30 CZ CZ20031855A patent/CZ20031855A3/cs unknown
- 2001-11-30 AU AU2002226366A patent/AU2002226366B2/en not_active Ceased
- 2001-11-30 JP JP2002547961A patent/JP2004525869A/ja active Pending
- 2001-11-30 EP EP07103384A patent/EP1806144A3/en not_active Withdrawn
- 2001-11-30 MX MXPA03005027A patent/MXPA03005027A/es active IP Right Grant
- 2001-11-30 UA UA2003076266A patent/UA83790C2/ru unknown
- 2001-11-30 IL IL15606901A patent/IL156069A0/xx unknown
- 2001-11-30 CA CA002428092A patent/CA2428092A1/en not_active Abandoned
-
2003
- 2003-05-23 HR HR20030426A patent/HRP20030426A2/hr not_active Application Discontinuation
- 2003-06-06 NO NO20032597A patent/NO20032597D0/no not_active Application Discontinuation
- 2003-06-25 BG BG107941A patent/BG107941A/bg unknown
-
2005
- 2005-03-04 HK HK05101882A patent/HK1068106A1/xx not_active IP Right Cessation
-
2007
- 2007-06-28 CY CY20071100851T patent/CY1107687T1/el unknown
- 2007-12-20 US US11/961,033 patent/US7655628B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1107687T1 (el) | Χρηση της sarp-1 για τη θεραπευτικη αντιμετωπιση και/ή προληψη της σκληροδερμιας | |
CY1108610T1 (el) | Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες | |
CY1107615T1 (el) | Θεραπευτικοι συνδυασμοι αντιυπερτασικων και αντιαγγειογενετικων παραγοντων | |
CY1111237T1 (el) | Χρηση πραμιπεξολης για αντιμετωπιση αμυοτροφικης πλευρικης σκληρυνσης | |
CO5611160A2 (es) | Conjugados de agentes terapeuticos o citotoxicos y peptidos biologicamente activos | |
BR0314354A (pt) | Formação para gentes lipofìlicos | |
CY1106156T1 (el) | Νεα χρηση βουδεσονιδης και φορμοτepολης | |
NO307968B1 (no) | Pyrazolo- og pyrrolopyridiner og farmasøytisk blanding derav | |
CY1108007T1 (el) | Φαρμακευτικες συνθεσεις βοτουλινικης τοξινης | |
CY1108274T1 (el) | Μακροβιο ομοιαζον με γλυκογονο πεπτιδιο 2 (glp-2) για την θεραπεια γαστρεντερικων ασθενειων και διαταραχων | |
CY1107242T1 (el) | Μυριστικο κητυλιο και παλμικο κητυλιο για τη θεραπεια του εκζεματος ή/και της ψωριασης | |
ATE245977T1 (de) | Therapeutische substituierte guanidine | |
ATE445389T1 (de) | Liposomale glucocorticoide | |
DE69905170T2 (de) | Thiazolopyrimidinderivate | |
ES2192839T3 (es) | Timosina beta 4 oxidada. | |
RS51737B (sr) | Korišćenje inhibitora il-18 | |
SE0002202D0 (sv) | New peptides | |
PT1390371E (pt) | Oxazolo- e furopirimidinas e sua utilizacao em medicamentos contra tumores | |
BR0211186A (pt) | peptìdeos e uso dos mesmos no escurecimento da pele | |
SE9700934D0 (sv) | New formulation | |
NO20073914L (no) | Biologisk aktive peptider | |
MY130445A (en) | Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone | |
PT1150703E (pt) | Terapia de esclerose multipla com chaperonina 10 e beta-interferao | |
ATE374203T1 (de) | Therapeutische verbindungen und verfahren | |
EA200000909A1 (ru) | ФОРМА VI 5,6-ДИХЛОР-2-(ИЗОПРОПИЛАМИНО)-1-(b-L-РИБОФУРАНОЗИЛ)-1H-БЕНЗИМИДАЗОЛА |